The Role of Mirtazapine in the Pathogenesis and Therapy of Chronic Liver Disease
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Depression is a common comorbidity in patients with chronic liver disease (CLD) and is associated with poorer clinical outcomes. Due to concerns about hepatic metabolism and limited tolerability, the use of traditional antidepressants is often restricted. Mirtazapine is a noradrenergic and specific serotonergic antidepressant. Driven by its unique rigid tetracyclic scaffold and enantiomeric properties, Mirtazapine exhibits multi-target binding that may affect multiple shared pathways in CLD and depression. Preclinical studies have shown that in models of metabolic Dysfunction-Associated Steatotic Liver Disease, cirrhosis, and hepatocellular carcinoma, Mirtazapine can attenuate liver tissue injury, suppress hepatic stellate cell activation, and modulate inflammatory responses and oxidative stress levels. Additionally, the drug may provide indirect clinical benefits by alleviating patients' depressive symptoms, improving sleep quality, and promoting appetite recovery. However, mirtazapine is consistently associated with a range of metabolic adverse effects, including weight gain, insulin resistance, and hepatic steatosis. These effects may exacerbate the metabolic burden in patients with CLD, thereby limiting its clinical utility. Therefore, when prescribing this agent to patients with comorbid depression, clinicians must carefully balance its anti-inflammatory and anti-fibrotic benefits against metabolic risks to achieve rational individualized medication.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- The Role of Mirtazapine in the Pathogenesis and Therapy of Chronic Liver Disease
- Date Crossref
- 05/08/2026
- Éditeur
- Bentham Science Publishers Ltd.
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Central South University Department of Gastroenterology pays non établi dans la noticeUniversité ou école supérieure
-
National Clinical Research Center for Digestive Diseases pays non établi dans la noticeÉtablissement de santé
-
Second Xiangya Hospital of Central South University pays non établi dans la noticeÉtablissement de santé
-
Second People Hospital of Hunan pays non établi dans la noticeÉtablissement de santé
-
Xian Yang Central Hospital pays non établi dans la noticeÉtablissement de santé
-
Clinical Research Center for Digestive Diseases in Hunan Province pays non établi dans la noticeStructure de recherche
-
The Second People's Hospital of Hunan Province Department of Psychiatry pays non établi dans la noticeÉtablissement de santé
Department of Gastroenterology — Central South University, National Clinical Research Center for Digestive Diseases et Second Xiangya Hospital of Central South University, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.